Beyond the Database: Turning Clinical Trial Data Into Strategic Advantage
Panel discussion summary

Clinical trial data is more than a regulatory deliverable — it is a long-term strategic asset. This panel explores how early- and mid-stage biotech companies can move beyond database lock and build data infrastructures that enable scientific insight, cross-trial integration, and commercial leverage. Learn how structured data governance strengthens decision-making, accelerates partnerships, and directly impacts company valuation in competitive markets.

Date, time and room information

Monday, May 4, 17:30 - 18:15, room Kairo

Moderation
Name Position Institution
Cornelia Baumgartner Owner and Founder of Cetacea Clinical Cetacea Clinical GmbH
Panelists
Name Position Institution
Dr. Ulf Grawunder CEO T-CURX GmbH
Elisabeth Steiger Senior Director Clinical Data ManagemenT Metronomia GmbH
Royden James Chief Product Officer Viedoc
Dr. Günter Fingerle- Rowson Chief Medical Officer Tubulis Inc.
Metronomia GmbH

Metronomia is a leading biometrics-focused organization with global capabilities providing exceptional biostatistics, data management and medical writing services to biopharmaceutical companies.
The company supports Phase I–III clinical trials across multiple therapeutic areas, delivering regulatory-ready data packages aligned with global authority expectations.

Metronomia positions itself as a science-driven partner, emphasizing senior expertise, methodological rigor, and close collaboration with sponsors. Its integrated biometrics model ensures data integrity, statistical robustness, and efficient submission preparation — strengthenin

Cetacea Clinical GmbH

Cetacea Clinical is a Swiss-based boutique Clinical Operations consultancy providing hands-on operational leadership and Quality Management System (QMS) frameworks for early-stage biotech sponsors.

The company operates as a “Clinical Operations Department-in-a-box,” supporting first-in-human and early-phase trials with expertise in trial oversight, vendor management, regulatory coordination (CTIS, Swissmedic, FDA), and inspection readiness.

Cetacea’s proprietary Swiss-quality SOP architecture enables sponsors to build inspection-ready structures from day one — combining strategic thinking with pragmatic execution to ensure clinical prog